September 05, 2017
PARIS–(BUSINESS WIRE)–EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that it will introduce a new version of spineEOS, the Company’s online 3D planning software for spine surgery based on EOS stereo-radiographic 2D/3D imaging. spineEOS is the first software to incorporate biomechanical patient data into surgery simulation and planning to help physicians optimize the patient’s spinal treatment. It has received CE Mark approval in Europe and has been submitted to the U.S. Food and Drug Administration (FDA) for approval.
Marie Meynadier, CEO of EOS imaging, said, “Spine flexibility, which varies from patient to patient, is a key component of how a patient will react to spinal surgery. We are very excited to introduce, for the first time, biomechanical algorithms that take into account the specific flexibility of the patient spine, further improving the spineEOS treatment simulation and planning to accurately reflect the patient’s post-surgical reaction. We believe this will be particularly beneficial for patients with complex spinal disorders, where proper pre-operative simulation can help surgeons choose the right surgical strategy, optimize the shape and position of the implant across different spinal levels, and positively impact the final alignment and long-term outcomes.”
EOS imaging will introduce the new spineEOS software in a symposium during the Scoliosis Research Society (SRS) 52nd Annual Meeting & Course, which is taking place in Philadelphia, PA from September 6-9, 2017.
The symposium will be held on Thursday, September 7, 2017 from 4:45 to 6:00 pm EDT and will include presentations from the first physicians to utilize the new spineEOS software. The physicians presenting in the symposium include:
- Dr. Lawrence Lenke, New York Presbyterian/Columbia University Medical Center, New York
- Dr. Salil Upasani, Rady Children’s Hospital, San Diego
- Dr. Stefan Parent, Sainte Justine Hospital, Montréal
- Dr. Brice Ilharreborde, Robert Debré Hospital, APHP, Paris
For more information, please visit www.eos-imaging.com.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
About EOS imaging
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteo-articular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2016 revenues of €30.8 million and employs 132 people at December 2016, including an R&D team of 43 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.
Pierre Schwich, +33 (0)1 55 25 61 24
Chief Financial Officer
Financial communication and investor relations
Pierre Laurent / Valentine Brouchot, +33 (0)1 44 71 94 96
Annie-Florence Loyer, +33 (0)1 44 71 00 12 / 6 88 20 35 59
The Ruth Group (US)
Joanna Zimmerman, 646-536-7006